Popular Trials
Genetics Study for Type 2 Diabetes
Recruiting1 award4 criteria
Nashville, Tennessee
The TODAY study group has prepared a protocol with the primary objective of collecting blood and phenotypic information to be used to explore relationships between candidate genes and type 2 diabetes (T2D), as well as obesity, insulin resistance, and cardiovascular complications of insulin resistance. Participation in the genetics study includes a blood draw for analysis of diabetes type and DNA extraction, as well as collection of basic family and medical history. Appropriate informed consent and assent are obtained from all participants to extract DNA and send blood, genetic material, and medical history to the Central Repository of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The data are kept indefinitely by the Central Repository. The NIDDK will issue requests for proposals (RFP) throughout the scientific community for research that may help in the development of new diagnostic tests, new treatments, and new ways to prevent diabetes and other related comorbidities.
Omega-3 Supplement
Omega-3 Smoothies for Healthy Nutrition
Recruiting0 awards
Fort Campbell North, Kentucky
This trial aims to see how omega-3 supplements affect the physical performance and recovery of soldiers. Participants will be split into two groups - one taking omega-3 fortified smoothies and the other taking non
BCL-2 Inhibitor
Selinexor + Venetoclax + Chemotherapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing the safety and best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that has come back (relapsed) or did not respond to treatment (refractory).
Monoclonal Antibodies
Cemiplimab REGN2810 +1 More for Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new drug, SAR439459, for people with advanced solid tumors. Part 1 is testing how well the drug works and what the best dose is. Part 2 is expanding to see if the drug works well in people with a specific type of advanced melanoma.
Popular Filters
Phase 3 Trials
Prostacyclin Analogue
Oral treprostinil for Pulmonary Hypertension
Recruiting2 awardsPhase 3
Nashville, Tennessee
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects took the initial dose of study drug at the study site on the day of randomization. Subjects returned to the study site for visits scheduled at Weeks 6, 12, 18, and 24. The duration of study participation was approximately 28 weeks from Screening until study completion (includes a 30-day Screening Phase and 24-week Treatment Phase). The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment. As only a small portion of the anticipated total subjects had been enrolled, with many terminating early due to the study termination, there was a limited ability to explore the effect of oral treprostinil in this indication in this study.
Checkpoint Inhibitor
Nivolumab +1 More for Clear-cell Renal Cell Carcinoma
Recruiting2 awardsPhase 3
Nashville, Tennessee
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin +2 More for Type 2 Diabetes
Recruiting3 awardsPhase 3
Nashville, Tennessee
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Follicular Lymphoma
Recruiting2 awardsPhase 3
Nashville, Tennessee
This trial will compare ibrutinib + rituximab vs rituximab alone in people with untreated follicular lymphoma. The goal is to see if ibrutinib helps people live longer without the cancer progressing.
Taxane
Paclitaxel +2 More for Cervical Adenocarcinoma
Recruiting3 awardsPhase 3
Rome, Georgia
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical cancer that has come back or is persistent. Drugs used in chemotherapy, such as paclitaxel, cisplatin, and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer.
Trials With No Placebo
Radiation
Dabrafenib + Trametinib After Radiation for Brain Cancer
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
Diagnostic Test
Standard of Care Esophagogastroduodenoscopy (EGD) with Measurement of Mucosal Impedance for Acid Reflux
Recruiting1 award2 criteria
Nashville, Tennessee
Our hypothesis is that patients with GERD and/or Eosinophilic Esophagitis (EE) have lower esophageal impedance measurements when compared to patients who do not have GERD or EE.
Checkpoint Inhibitor
Nivolumab +1 More for Clear-cell Renal Cell Carcinoma
Recruiting2 awardsPhase 3
Nashville, Tennessee
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Immunomodulator
Abatacept for Juvenile Idiopathic Arthritis
Recruiting1 award5 criteria
Nashville, Tennessee
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Pentoxifylline for Kidney Failure
Recruiting3 awardsPhase 2
Columbia, Tennessee
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.